Drug Companies

 
Stock Quotes for Drug Companies top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 524689 investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for ankurdrugs investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for pdpl investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 530317 investment picks
  • Industry: Chemicals
  • Sector: Basic Materials
  • Stock Style: Small Value
Sign-up for 532637 investment picks

 
News Articles for Drug Companies top ^
Coverage gaps or caps on coverage generally did not result in health care savings Researchers urge policymakers to consider strategies other than limiting access to prescription drugs in efforts to reduce health care costs WOONSOCKET, R.I. , Jan.
Sign-up for CVS Health Research Institute Provides More Evidence that Broader Prescription Drug Coverage Improves Health Outcomes investment picks
2015/1/4
By Jonathan D.
Sign-up for Drug Prices to Get More Expensive -- Corporate Outlook investment picks
2014/12/23
By Maria Armental Danish drug maker Novo Nordisk A/S's (NVO) injectable diabetes drug has been approved in the U.S. to fight obesity, the Food and Drug Administration said Tuesday.
Sign-up for FDA Approves Novo Nordisk Diabetes Drug's Use to Fight Obesity investment picks
Spectrum Pharmaceuticals (Nasdaq: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Captisol-Enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Sign-up for Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). “Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.
Sign-up for Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for Ignyta’s lead product candidate entrectinib for the treatment of neuroblastoma.
Sign-up for Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Captisol-enabled™ Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Sign-up for Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan investment picks
- 10-year Federal Contract Award Valued at up to $37 Million - ALBANY, N.Y. , Jan.
Sign-up for AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and Clinical Drug Product investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults.
Sign-up for Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted teduglutide orphan drug designation for the treatment of Short Bowel Syndrome (SBS). Also, due to the strong medical need for SBS treatments in Japan, the MHLW’s expert committee on Unapproved New Drugs and New Indications with High Medical Needs requested that NPS Pharma Japan K.K. develop teduglutide for adult SBS earlier this year.
Sign-up for Teduglutide Granted Orphan Drug Designation in Japan investment picks
Generic biotech drugs took one step closer to reality after a Food and Drug Administration advisory panel recommended the agency approve a Novartis AG (NVS) version of Amgen's Inc.'s (AMGN) drug Neupogen, according to media reports late Wednesday.
Sign-up for UPDATE: FDA panel recommends approval for first generic biotech drug investment picks
Generic biotech drugs took one step close to reality after a Food and Drug Administration advisory panel recommended the agency approve a Novartis AG (NVS) version of Amgen's Inc.'s (AMGN) drug Neupogen, according to media reports late Wednesday.
Sign-up for FDA panel recommends approval for first generic biotech drug investment picks
2014/12/21
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical Experience Radius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA Submission in the Second Half of 2015 Radius' Investigational Drug Abaloparatide Transdermal Program Achieves Key Milestone in its Development as a Post-Approval Line Extension Company to Host Conference Call Tomorrow (Monday, December 22, 2014) at 8:00 a.m. ET WALTHAM, Mass., Dec.
Sign-up for Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Drug Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Driving Sales  |  Next: Drug Delivery Shares